Get Started

BCYC

NASD Bicycle Therapeutics Plc Sponsored ADR
Nov 4, 2026 · 1:54 PM ET DELAYED Market Open

$3.73 ↑ +0.06 (+1.63%) Trading Up from the previous close of $3.67, $0.07 below the day’s high of $3.80

YTD change
-47.32%
vs 20-day SMA
+1.63%
vs 200-day SMA
-17.76%

Price ranges

Previous day
$3.61 $3.71
open $3.61 close $3.67
+$0.06 (+1.66%)
Today
$3.65 $3.80
open $3.75 now $3.73
-$0.02 (-0.53%)
Past week
$3.58 $4.14
from $3.78 now $3.73
-$0.05 (-1.32%)
Past month
$3.41 $4.14
from $3.79 now $3.73
-$0.06 (-1.58%)
This year
$3.33 $7.34
from $7.08 now $3.73
-$3.35 (-47.32%)

Price & Performance

-1.27 (-25.71%) / 6M

$3.24$3.92$4.61$5.29May 4Aug 4Nov 3

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 94.0% away from all-time highs of $62.08
  • BCYC is down 47% since the beginning of the year
  • BCYC is down 46% over the past 12 months
  • BCYC is down 2% over the past 1 month
  • 5% of all BCYC investors are betting against BCYC

BCYC reads not so good: price sits above one of the two key moving averages, the 12-month move is -46.6%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.15
Earnings momentum +66.1% Quarterly EPS growth
Quarterly change +66.1%

Valuation

P/E ratio N/A
Enterprise value $-198435000.0
Beta 1.74

Balance sheet & scale

IncomeN/A
Revenue$83.6M
Cash$469.9M
Debt$14.7K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $188.6M

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $461.26 -0.90%
MRNA Moderna, Inc. $228.44 +3.45%
RVMD Revolution Medicines, Inc. $194.23 +3.22%
ROIV Roivant Sciences Ltd. $36.04 +0.42%
BNTX BioNTech SE Sponsored ADR $86.92 -0.70%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.